全球流感診斷與治療市場：未來預測（2025-2030）

流感診斷和治療市場預計將從 2025 年的 427.19 億美元成長到 2030 年的 613.42 億美元，複合年成長率為 7.50%。

預計未來五年，流感診斷和治療市場將迎來顯著成長，這得益於全球流感高發，尤其是在醫療保健資源匱乏的地區。主要市場參與企業加大研發投入，以提高產品品質並拓展產品組合，預計將在預測期（2024-2029年）進一步推動市場成長。市場對改善健康狀況（尤其是高風險族群健康）的日益關注，支撐了市場的擴張。

主要成長要素

全球不斷攀升的流感疫情仍是市場成長的主要驅動力。在北美，甲型流感病毒佔據主導地位，約佔成人流感住院病例的80%。歐洲和亞太等地區流感發生率的上升也顯著推高了市場需求。流感具有傳染性，其特徵是發燒、喉嚨痛、乾咳和肌肉酸痛等症狀，可能導致老年人、孕婦、嬰兒和免疫力缺乏低下者等弱勢群體患上重病甚至死亡，這加劇了對有效診斷和治療方案的需求。

全球人口老化，尤其是在日本、義大利和德國等國家，進一步推動了市場成長。免疫力較弱的長者需要加強流感診斷和治療，這增加了對專業套件和服務的需求。這些地區擁有完善的醫療保健體系，這推動了先進診斷和治療解決方案的採用。

目錄

第1章執行摘要

第2章市場概述

• 市場概覽
• 市場定義
• 分析範圍
• 市場區隔

第3章 商業景氣

• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析
• 產業價值鏈分析
• 政策法規
• 策略建議

第4章 技術展望

5. 全球流感診斷與治療市場（以流感類型）

• 介紹
• A型
• B型
• 其他

6. 全球流感診斷與治療市場（依產品提供）

• 介紹
• 診斷
  • 快速流感診斷檢測
  • 快速分子檢測
  • RT-PCR和NAAT
  • 螢光試驗
  • 家用流感檢測套組
• 治療
  • 抗病毒藥物
  • 疫苗
  • 其他

7. 全球流感診斷與治療市場（依年齡層）

• 介紹
• 0-14歲
• 15-64歲
• 65歲或以上

8. 全球流感診斷與治療市場（依給藥方式）

• 介紹
• 口服
• 鼻內
• 注射

9. 全球流感診斷與治療市場（依最終使用者）

• 介紹
• 醫院和醫院檢查室
• 門診
• 藥局和零售診所
• 參考實驗室
• 居家醫療/自我檢測用戶

第10章 全球流感診斷與治療市場（按地區）

• 介紹
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 其他
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 印尼
  • 泰國
  • 其他

第10章競爭格局及分析

• 主要企業和策略分析
• 市場佔有率分析
• 企業合併（M&A）、協議與合作
• 競爭儀錶板

第11章 公司簡介

• QuidelOrtho Corporation
• F. Hoffmann-La Roche AG
• Becton, Dickinson and Company
• Thermo Fisher Scientific Inc.
• SA Scientific, Ltd.
• Sekisui Diagnostics, LLC
• Meridian Bioscience, Inc.
• Oxford Biosystems Ltd.
• Pfizer Inc.
• Bayer AG
• GlaxoSmithKline plc
• Abbott Laboratories
• Danaher Corporation
• Sanofi SA
• Hologic, Inc.
• Luminex Corporation
• DiaSorin SpA

第12章 附錄

• 貨幣
• 先決條件
• 基準年和預測年時間表
• 相關人員的主要利益
• 分析方法
• 簡稱

The Global Flu Diagnostic And Treatment Market is expected to grow from USD 42.719 billion in 2025 to USD 61.342 billion in 2030, at a CAGR of 7.50%.

The global flu diagnostic and treatment market is expected to experience significant growth over the next five years, driven by the high prevalence of influenza worldwide, particularly in regions with limited healthcare access. Rising investments in research and development by key market players to enhance product quality and expand offerings are anticipated to further propel market growth during the forecast period (2024-2029). The focus on improving health outcomes, especially for high-risk populations, underscores the market's expansion.

Key Growth Drivers

The increasing prevalence of influenza globally remains a primary driver of market growth. In North America, influenza A viruses dominate, accounting for approximately 80% of adult influenza-related hospitalizations. The growing incidence of flu in regions such as Europe and Asia Pacific also contributes significantly to market demand. The need for effective diagnostic and treatment solutions is amplified by the disease's contagious nature, characterized by symptoms like fever, sore throat, dry cough, and muscle pain, which can lead to severe illness or death in vulnerable groups, including the elderly, pregnant women, infants, and immunocompromised individuals.

The aging global population, particularly in countries like Japan, Italy, and Germany, further fuels market growth. Older adults, with weaker immune systems, require enhanced flu diagnostics and treatments, increasing demand for specialized kits and services. Well-established healthcare systems in these regions support the adoption of advanced diagnostic and treatment solutions.

Market Segmentation

By Flu Type

• The market is segmented into Type A and Type B influenza viruses. Type A dominates due to its higher prevalence and greater number of clinically diagnosed cases and hospitalizations compared to Type B. The Type A segment is expected to maintain a significant market share through 2029. While Type B flu has a lower incidence, its growing prevalence, particularly in the Asia Pacific region, is anticipated to drive modest growth in this segment over the forecast period.

By End-User

• The market is categorized into hospital laboratories, outpatient clinics, and reference laboratories. Outpatient clinics are projected to exhibit notable growth due to their cost-effective, point-of-care treatment offerings. Hospital laboratories, however, are expected to retain a significant market share, driven by their ability to provide long-term care and perceived reliability. Reference laboratories also contribute to the market but to a lesser extent.
• Geographical Outlook
• The Asia Pacific region is poised for robust growth, fueled by the rising prevalence of influenza in countries like India, China, and Indonesia, coupled with increasing healthcare expenditure in developing nations. North America is expected to maintain a substantial market share, supported by well-established healthcare systems in the U.S. and Canada and high healthcare spending. These factors collectively position North America and Asia Pacific as key regions driving the global flu diagnostic and treatment market through 2029.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
• What do businesses use our reports for?
• Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Global Flu Diagnostic and Treatment Market Segmentation:

By Type of Flu

• Type A
• Type B
• Others

By Offering

• Diagnostics
• Rapid Influenza Diagnostic Test
• Rapid Molecular Assay
• RT-PCR & NAATs
• Immunofluorescence Assays
• At-Home Flu Testing Kits
• Therapeutics
• Antiviral Medications
• Vaccines
• Others

By Age Group

• 0-14 Years
• 15-64 Years
• >=65 Years

By Mode of Administration

• Oral
• Intranasal
• Injectable

By End-User

• Hospitals & Hospital Laboratories
• Outpatient Clinic
• Pharmacies & Retail Clinics
• Reference Laboratories
• Home Care/Self-Test Users

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• Israel
• UAE
• Other
• Asia Pacific
• China
• Japan
• South Korea
• India
• Thailand
• Indonesia
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY TYPE OF FLU

• 5.1. Introduction
• 5.2. Type A
• 5.3. Type B
• 5.4. Others

6. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY OFFERING

• 6.1. Introduction
• 6.2. Diagnostics
  • 6.2.1. Rapid Influenza Diagnostic Test
  • 6.2.2. Rapid Molecular Assay
  • 6.2.3. RT-PCR & NAATs
  • 6.2.4. Immunofluorescence Assays
  • 6.2.5. At-Home Flu Testing Kits
• 6.3. Therapeutics
  • 6.3.1. Antiviral Medications
  • 6.3.2. Vaccines
  • 6.3.3. Others

7. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY AGE GROUP

• 7.1. Introduction
• 7.2. 0-14 Years
• 7.3. 15-64 Years
• 7.4. >=65 Years

8. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY MODE OF ADMINISTRATION

• 8.1. Introduction
• 8.2. Oral
• 8.3. Intranasal
• 8.4. Injectable

9. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY END-USER

• 9.1. Introduction
• 9.2. Hospitals & Hospital Laboratories
• 9.3. Outpatient Clinic
• 9.4. Pharmacies & Retail Clinics
• 9.5. Reference Laboratories
• 9.6. Home Care/Self-Test Users

10. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

• 10.1. Introduction
• 10.2. North America
  • 10.2.1. USA
  • 10.2.2. Canada
  • 10.2.3. Mexico
• 10.3. South America
  • 10.3.1. Brazil
  • 10.3.2. Argentina
  • 10.3.3. Others
• 10.4. Europe
  • 10.4.1. Germany
  • 10.4.2. France
  • 10.4.3. United Kingdom
  • 10.4.4. Spain
  • 10.4.5. Others
• 10.5. Middle East and Africa
  • 10.5.1. Saudi Arabia
  • 10.5.2. UAE
  • 10.5.3. Others
• 10.6. Asia Pacific
  • 10.6.1. China
  • 10.6.2. India
  • 10.6.3. Japan
  • 10.6.4. South Korea
  • 10.6.5. Indonesia
  • 10.6.6. Thailand
  • 10.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. QuidelOrtho Corporation
• 11.2. F. Hoffmann-La Roche AG
• 11.3. Becton, Dickinson and Company
• 11.4. Thermo Fisher Scientific Inc.
• 11.5. SA Scientific, Ltd.
• 11.6. Sekisui Diagnostics, LLC
• 11.7. Meridian Bioscience, Inc.
• 11.8. Oxford Biosystems Ltd.
• 11.9. Pfizer Inc.
• 11.10. Bayer AG
• 11.11. GlaxoSmithKline plc
• 11.12. Abbott Laboratories
• 11.13. Danaher Corporation
• 11.14. Sanofi S.A.
• 11.15. Hologic, Inc.
• 11.16. Luminex Corporation
• 11.17. DiaSorin S.p.A.

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key Benefits for the Stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations